Skip to main content
Full access
Case Reports
Published Online: 4 October 2018

Continuing Clozapine Treatment in Acute Psychosis With Neutropenia

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Treatment-resistant schizophrenia, or lack of response to treatment, was first described in 1988.1 It is defined as schizophrenia symptoms treated in three phases with different antipsychotics at adequate doses for at least 6 weeks per phase without at least a 20% reduction in symptoms. About one-third of patients with schizophrenia are diagnosed with the treatment-resistant form of the disorder,2 reflecting two illness subtypes: treatment-resistant schizophrenia and treatment-responsive schizophrenia.3
Clozapine is the best evidence-based therapeutic option with an indication for treatment-resistant schizophrenia.4 Results of multiple clinical studies suggest that clozapine is effective in reducing hospital admissions, suicidality, and aggressive behavior when compared with other antipsychotics.5,6 However, it could lead to serious hematological side effects, such as neutropenia or agranulocytosis. According to previous consensus,7 discontinuation of clozapine is recommended with the occurrence of neutropenia, when the white blood cell (WBC) count falls below 3×103/uL or the absolute neutrophil count falls below 1.5×103/uL during first-time clozapine use. After considering the benefits and risks, rechallenge after complications are resolved has been occasionally attempted for patients with psychotic symptoms.8
We describe the case of a patient who developed neutropenia after starting clozapine. The patient’s treatment team continued clozapine at lower doses combined with typical antipsychotics. After closely monitoring her absolute neutrophil count, her psychotic symptoms improved without another episode of neutropenia or agranulocytosis.

Case Report

A 41-year-old unemployed, single Asian woman presented to our clinic. She had a history of schizoaffective disorder, with onset at age 27. She had been treated with antipsychotics and mood stabilizers, including haloperidol, sulpiride, clotiapine, quetiapine, olanzapine, risperidone, paliperidone, and aripiprazole, since age 37 but with inadequate treatment response, thereby fulfilling the criteria for treatment-resistant or refractory psychosis.9 She was a hepatitis B carrier with a history of diabetes mellitus under regular medication. No family history of psychosis and no previous head trauma or other organic brain disorders were reported. She had been living in a halfway house in recent years and was hospitalized in the acute psychiatric ward approximately once every 2 years for exacerbated psychosis with disturbing behavior. She refused treatment with ECT.
Despite compliance with the treatment regimen, the patient’s symptoms worsened. Consequently, her treatment team decided to start her on clozapine (50 mg/day) during outpatient assessment, which was 6 days before her hospital admission. Laboratory assessment indicated normal WBC and neutrophil counts (6.23×103/uL and 3.95×103/uL, respectively). On admission, which was day 6 of clozapine use, her dosage was titrated to 100 mg/day, with close monitoring, and the patient’s WBC and neutrophil counts were 3.14×103/uL and 1.66×103/uL, respectively. On day 7, a drop was detected in both WBC (2.78×103/uL) and neutrophil (1.48×103/uL) counts, without any subjective discomfort or signs of infection. Her score on the Naranjo Adverse Drug Reaction Probability Scale was 7, corresponding to a probable adverse clozapine-associated effect of neutropenia.10 The patient maintained clozapine use at lower doses (75 mg/day), after the potential benefits and risks were weighed. Her WBC and neutrophil counts were closely monitored twice a week during the first 2 weeks, and the counts remained within the normal range (4.28×103/uL and 6.72×103/uL, respectively, on day 8). The treatment team tapered clozapine to 50 mg/day and combined it with trifluoperazine (5 mg/day) during the third week because the patient began to experience a sore throat and cough.
She was asymptomatic after 4 weeks of treatment and was discharged from the hospital with improved psychotic symptoms. She received regular outpatient follow-up for several months. She remained in remission without any adverse effects under the same regimen, with regular monitoring of her WBC count (>4×103/uL) and without another episode of neutropenia or agranulocytosis.

Discussion

The above case of treatment-resistant schizophrenia provides a strategy for managing neutropenia during clozapine use by tapering the dosage and combining it with typical antipsychotics. However, continuing clozapine treatment is potentially risky when hematological side effects occur.
Clozapine-induced neutropenia can be divided into three types: pseudo, benign, and malignant. The malignant type raises serious concerns and can necessitate discontinuing clozapine use.11 Risk factors for developing neutropenia in patients taking clozapine include younger age and male sex,12 and it also has a higher potential occurrence among people of African origin.13 Clozapine is virtually the only medication with an evidence-based effect on refractory psychosis. Therefore, under certain conditions, clozapine rechallenge is considered to be the only effective treatment. The risks and benefits of rechallenge and any other options must be weighed carefully. Clozapine has been successfully rechallenged with lithium or granulocyte colony stimulating factor (G-CSF).
Rechallenge of clozapine with lithium to increase the neutrophil count and total WBC count may be beneficial. A brief review14 suggested that continuing clozapine treatment with lithium in patients with schizophrenia with neutropenia or leukopenia may be a successful strategy. Increased serious side effects related to lithium and clozapine were not observed.
Clozapine has also been successfully rechallenged after neutropenia in combination with G-CSF.15 However, the method of use of G-CSF—whether as a single or occasional dose or in regular prophylactic use—was uncertain. Moreover, the risk of side effects caused by G-CSF, including bone pain and autoimmune disorders, should be considered.
One study16 reported that clozapine, compared with other antipsychotics, is known for contributing to higher risk for neutropenia, even when patients are receiving a number of drugs or have an underlying undetected hematological disorder. Concomitant drug therapy and drug-drug interactions may be underestimated. There are few studies on continuing clozapine use without adjuvant medication. A case report17 demonstrated that rechallenge with clozapine after 2 days had no adverse effects. One study suggested that clozapine bioactivation caused dose-dependent inhibition of stromal viability, eventually resulting in the death of human bone marrow stromal cells in vitro.18 Another study showed that clozapine-related neutropenia through cell apoptosis was caused by cells binding nitrenium molecules in vitro and characterized by dose-dependent toxicity.19
The present case report adds to the limited evidence on continuing clozapine treatment for psychosis with neutropenia. After considering the benefits and risks of administering nonantipsychotic medication, such as lithium or G-CSF, the treatment team successfully used lower doses of clozapine, combined with typical antipsychotics, in a patient with treatment-resistant schizophrenia following an episode of neutropenia. For optimal treatment of refractory schizophrenia, further investigations should focus on innovative, evidence-based pharmacological strategies.

References

1.
Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796
2.
Suzuki T, Remington G, Mulsant BH, et al: Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012; 197:1–6
3.
Gillespie AL, Samanaite R, Mill J, et al: Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry 2017; 17:12
4.
Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(suppl 2):1–56
5.
Gee S, Vergunst F, Howes O, et al: Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014; 130:16–24
6.
Stroup TS, Gerhard T, Crystal S, et al: Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with achizophrenia. Am J Psychiatry 2016; 173:166–173
7.
Dunk LR, Annan LJ, Andrews CD: Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188:255–263
8.
Manu P, Sarpal D, Muir O, et al: When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? a systematic review of the published literature. Schizophr Res 2012; 134:180–186
9.
Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50:898–911
10.
Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239–245
11.
Bogers JP: Granulocytopenia while using clozapine: continuing or stopping treatment. Tijdschr Psychiatr 2007; 49:575–579
12.
Maher KN, Tan M, Tossell JW, et al: Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2013; 23:110–116
13.
Munro J, O’Sullivan D, Andrews C, et al: Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175:576–580
14.
Aydin M, Ilhan BC, Calisir S, et al: Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Ther Adv Psychopharmacol 2016; 6:33–38
15.
Khan AA, Harvey J, Sengupta S: Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia. Ther Adv Psychopharmacol 2013; 3:266–271
16.
Simon L, Cazard F: Clozapine rechallenge after neutropenia in resistant schizophrenia: a review. Encephale 2016; 42:346–353
17.
Bavle A, Vidhyavathi M: Case report of clozapine-induced neutropenia and rechallenge. J Neuropsychiatry Clin Neurosci 2015; 27:e61
18.
Pereira A, Dean B: Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 2006; 72:783–793
19.
Pessina A, Turlizzi E, Bonomi A, et al: In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006; 39:20–22

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 95 - 96
PubMed: 30282512

History

Received: 22 June 2018
Revision received: 2 July 2018
Revision received: 31 July 2018
Revision received: 20 August 2018
Accepted: 20 August 2018
Published online: 4 October 2018
Published in print: Winter 2019

Keywords

  1. Clozapine
  2. Neutropenia
  3. Agranulocytosis

Authors

Details

Po-Chiao Liao, M.D.
From the Department of Psychiatry, Taipei Medical University Hospital, Taipei, Taiwan (P-C L, K-H C); Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan (K-H C); and the Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (K-H C).
Kuo-Hsuan Chung, M.D. [email protected]
From the Department of Psychiatry, Taipei Medical University Hospital, Taipei, Taiwan (P-C L, K-H C); Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan (K-H C); and the Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (K-H C).

Notes

Send correspondence to Dr. Chung; e-mail: [email protected]

Competing Interests

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share